Intratumoral administration of mRNA COVID-19 vaccine delays melanoma growth in mice.

ABSTRACT: Immunotherapies are effective for cancer treatment but are limited in 'cold' tumor microenvironments due to a lack of infiltrating CD8⁺ T cells, key players in the anti-cancer immune response. The onset of the COVID-19 pandemic sparked the widespread use of mRNA-formulated vaccines and is well documented that vaccination induces a Th1-skewed immune response. Here, we evaluated the effects of an intratumoral injection of the mRNA COVID-19 vaccine in subcutaneous melanoma tumor mouse models. Tumor growth and survival studies following a single intratumoral injection of the COVID-19 vaccine showed significant tumor suppression and prolonged survival in established B16F10 subcutaneous tumor-bearing mice. mRNA vaccine treatment resulted in a significant increase in CD8⁺ T

SUBMITTER: Boehm DT 

PROVIDER: S-EPMC11825918 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature